scholarly journals Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug

Oncotarget ◽  
2017 ◽  
Vol 8 (55) ◽  
pp. 94872-94882 ◽  
Author(s):  
Masashi Okada ◽  
Hiroyuki Takeda ◽  
Hirotsugu Sakaki ◽  
Kenta Kuramoto ◽  
Shuhei Suzuki ◽  
...  
2005 ◽  
Vol 32 (06) ◽  
Author(s):  
GU Höglinger ◽  
P Rizk ◽  
WH Oertel ◽  
EC Hisch

2021 ◽  
Vol 22 (3) ◽  
pp. 1154
Author(s):  
Yong-Ren Chen ◽  
Pei-Lun Lai ◽  
Yueh Chien ◽  
Po-Hui Lee ◽  
Ying-Hsiu Lai ◽  
...  

The authors regret to have made a mistake in publishing this paper [...]


2009 ◽  
Vol 85 (11) ◽  
pp. 955-962 ◽  
Author(s):  
Veerander P. S. Ghotra ◽  
Jordi C. Puigvert ◽  
Erik H. J. Danen

2021 ◽  
pp. 1-6
Author(s):  
Asuka Morizane ◽  
Jun Takahashi

Stem cell-based therapies for Parkinson’s disease are now being applied clinically. Notably, studies have shown that controlling the graft-induced immune response improves the results. In this mini-review, we concisely summarize current approaches used for this control. We focus on four modes of stem cell-based therapies: autologous transplantation, allogeneic transplantation with human leukocyte antigen-matching and allogeneic transplantation without, and finally the application of “universal” pluripotent stem cells. We also discuss immuno-suppressive treatments and the monitoring of immune reactions in the brain.


2021 ◽  
Author(s):  
Dhruv Mahendru ◽  
Ashish Jain ◽  
Seema Bansal ◽  
Deepti Malik ◽  
Neha Dhir ◽  
...  

Aim: The aim of the study was to evaluate the neuroprotective effect of bone marrow stem cell secretome in the 6-hydroxydopamine (6-OHDA) model of Parkinson's disease. Materials & methods: Secretome prepared from mesenchymal stem cells of 3-month-old rats was injected daily for 7 days between days 7 and 14 after 6-OHDA administration. After 14 days, various neurobehavioral parameters were conducted. These behavioral parameters were further correlated with biochemical and molecular findings. Results & conclusion: Impaired neurobehavioral parameters and increased inflammatory, oxidative stress and apoptotic markers in the 6-OHDA group were significantly modulated by secretome-treated rats. In conclusion, mesenchymal stem cells-derived secretome could be further explored for the management of Parkinson's disease.


2017 ◽  
Vol 07 (01) ◽  
Author(s):  
Sung S Choi ◽  
Gi Hyeong Ryu ◽  
Da H Kim ◽  
Dong Seok Lee ◽  
Seunghoon Lee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document